US health regulators will hold a meeting in July to decide if licensed compounding pharmacies can make more types of peptides. The review will look at several compounds, including BPC-157 and epitalon, which were restricted in 2023 because of safety concerns and limited testing in people. The expert panel will meet on 23 and 24 July.

Peptides have become popular for fitness, anti-ageing, and weight loss, but there is not enough clinical evidence for many claims. Some people want pharmacies to make these products to improve safety, while others worry about health risks.

This review is important for regulators, as they must balance consumer demand with safety rules. The panel’s conclusions may guide future policy on peptide products in the wellness market.